Planta Med 2016; 82(S 01): S1-S381
DOI: 10.1055/s-0036-1596944
Abstracts
Georg Thieme Verlag KG Stuttgart · New York

Hepatoprotective activity and standardization of the bioactive lignan fraction of Linum usitatissimum L.

H El-Askary
1   Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr-El-Ainy St., 11562, Cairo, Egypt
,
S El Zalabani
1   Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr-El-Ainy St., 11562, Cairo, Egypt
,
RS El-Din
1   Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr-El-Ainy St., 11562, Cairo, Egypt
,
MY Issa
1   Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr-El-Ainy St., 11562, Cairo, Egypt
,
RR Hegazy
2   Pharmacology Department, Medical Division, National research center, Cairo, Egypt
,
A Hassan
3   Department of Pathology, Faculty of veterinary medicine, Cairo University
› Author Affiliations
Further Information

Publication History

Publication Date:
14 December 2016 (online)

 

Hepatoprotective efficiency of linseed (Linum usitatissimum L.) was in-vitro and in-vivo, assessed using silymarin (S) as positive control. Linseed was defatted with petroleum ether (PE) then extracted with 70% ethanol (E). Lignan fractions (LAl and LAc) were, respectively, obtained from alkaline and acid hydrolysates of (E). In-vitro evaluation on CCl4-injured human hepatoma cell-line (Huh7), revealed that all samples (at 10,100,1000 µg/ml for samples & 100 µg/ml for S), significantly ameliorated AST, ALT and GSH; meanwhile, highest increase in SOD was recorded for LAl, which was in-vivo tested (at 100, 200, 400 mg/kg b.wt.) on CCl4 liver-injured rats beside its parent extract E (at 200, 400, 800 mg/kg, relative to S at100 mg/kg). Biochemical (AST, ALT and total bilirubin) and histopathological changes were recorded. In vivo testing showed significant inhibition for ALT, AST and total bilirubin. Histological examination revealed the efficiency of linseed in preventing CCl4-induced inflammation, necrosis and vacuolation. The lignan fraction of alkaline hydrolysate (LAl) showed the highest hepatoprotective activities. Secoisolariciresinol diglucoside, (SDG) was isolated from LAl and was assessed, in-vitro and in-vivo (15, 30, 60 mg/kg), by adopting the same previous experimental protocols where it exerted a significant protection (93 – 129% that of S) against CCl4-induced liver injury. A simple and reliable RP-HPLC method was developed and validated for the quantification of SDG (the major bioactive constituent, 33%) in LAl. The recovery of the method was 100.9% and a high degree of precision (relative standard deviation values < 5%) was achieved. The limit of detection and quantitation were 3.11 µg/ml and 10.36 µg/ml, respectively. The method is sensitive and valuable for the commercial quality control of linseed extract and its preparations.

Keywords: Linseed, hepatoprotective, lignan, validation, SDG, Linum usitatissimum.